Double maintains 3 strategies that include EXEL - Exelixis, Inc.
Current Value
$44.411 Year Return
Current Value
$44.411 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FENG | 0.02% | $12.58M | -16.79% | 0.00% |
| GTN | 0.02% | $495.73M | -5.07% | 6.50% |
| RDUS | 0.04% | $835.63M | +86.59% | 2.53% |
| MSIF | -0.04% | $769.47M | +36.17% | 7.61% |
| EL | -0.06% | $31.87B | -16.78% | 1.91% |
| WBTN | -0.06% | $1.22B | -53.77% | 0.00% |
| DFDV | 0.06% | $300.56M | +2,130.16% | 0.00% |
| DAO | 0.08% | $262.76M | +119.32% | 0.00% |
| MEOH | -0.10% | $2.31B | -30.23% | 2.16% |
| WHWK | 0.11% | $88.57M | +34.29% | 0.00% |
| OSCR | -0.11% | $4.23B | -2.64% | 0.00% |
| KNDI | 0.12% | $93.72M | -48.58% | 0.00% |
| LX | 0.13% | $925.49M | +320.48% | 2.62% |
| CGEM | 0.13% | $457.95M | -53.75% | 0.00% |
| PSLV | 0.14% | - | - | 0.00% |
| JBI | -0.14% | $1.26B | -28.39% | 0.00% |
| ANIP | -0.15% | $1.41B | +7.23% | 0.00% |
| ABCL | 0.17% | $1.12B | +38.38% | 0.00% |
| FUTU | 0.19% | $13.57B | +79.03% | 0.00% |
| VSA | 0.25% | $8.67M | -19.04% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DAVA | -16.64% | $687.01M | -48.53% | 0.00% |
| AIFU | -15.42% | $6.79B | +102.19% | 0.00% |
| TXO | -12.11% | $840.39M | -26.57% | 15.39% |
| LEGN | -10.89% | $6.61B | -21.78% | 0.00% |
| SGC | -10.80% | $171.97M | -44.34% | 5.09% |
| BGFV | -10.25% | $32.35M | -43.60% | 0.00% |
| LITB | -9.60% | $21.24M | -78.57% | 0.00% |
| EXK | -8.81% | $1.47B | +33.33% | 0.00% |
| AGI | -8.68% | $11.34B | +67.62% | 0.37% |
| OPCH | -8.60% | $5.08B | +15.10% | 0.00% |
| SMCI | -8.40% | $29.09B | -42.46% | 0.00% |
| ATNI | -8.28% | $261.42M | -23.13% | 5.78% |
| WST | -8.22% | $15.89B | -31.06% | 0.37% |
| ODP | -7.77% | $598.64M | -49.76% | 0.00% |
| STG | -7.74% | $30.78M | -22.51% | 0.00% |
| HRMY | -7.56% | $1.84B | +3.95% | 0.00% |
| GIFI | -7.40% | $110.65M | +7.91% | 0.00% |
| AGL | -7.17% | $989.35M | -60.10% | 0.00% |
| SAGE | -7.15% | $568.61M | -14.50% | 0.00% |
| CNDT | -7.09% | $448.27M | -16.82% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FBT | 33.11% | $1.01B | 0.54% |
| PBE | 32.62% | $223.19M | 0.58% |
| SMMV | 30.03% | $317.06M | 0.2% |
| DVY | 29.83% | $19.69B | 0.38% |
| CDC | 28.99% | $733.71M | 0.42% |
| FTCS | 28.57% | $8.40B | 0.52% |
| XMLV | 28.54% | $810.02M | 0.25% |
| MDIV | 28.39% | $444.57M | 0.75% |
| XPH | 28.38% | $147.96M | 0.35% |
| LGLV | 28.32% | $1.09B | 0.12% |
| OUSA | 27.92% | $814.35M | 0.48% |
| FDLO | 27.86% | $1.22B | 0.16% |
| IXG | 27.76% | $527.14M | 0.41% |
| XLF | 27.70% | $50.10B | 0.09% |
| SPLV | 27.70% | $7.68B | 0.25% |
| FVD | 27.55% | $8.98B | 0.61% |
| VFH | 27.46% | $12.51B | 0.09% |
| DLN | 27.40% | $5.01B | 0.28% |
| IYG | 27.35% | $1.81B | 0.39% |
| IBB | 27.15% | $5.26B | 0.45% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -20.41% | $99.63M | 0.59% |
| VIXY | -18.73% | $164.54M | 0.85% |
| IVOL | -12.35% | $347.03M | 1.02% |
| BTAL | -12.09% | $296.22M | 1.43% |
| CTA | -9.86% | $1.06B | 0.76% |
| TBLL | -9.58% | $2.13B | 0.08% |
| SHYD | -8.53% | $332.63M | 0.35% |
| FXE | -8.00% | $568.94M | 0.4% |
| BILS | -7.79% | $3.81B | 0.1356% |
| GBIL | -7.70% | $6.37B | 0.12% |
| BIL | -6.51% | $42.24B | 0.1356% |
| BAR | -6.39% | $1.11B | 0.1749% |
| IAU | -6.30% | $46.70B | 0.25% |
| SGOL | -6.27% | $5.17B | 0.17% |
| OUNZ | -6.25% | $1.73B | 0.25% |
| SGOV | -6.19% | $49.21B | 0.09% |
| GLD | -6.17% | $100.19B | 0.4% |
| SHYM | -6.16% | $357.13M | 0.35% |
| AAAU | -6.13% | $1.54B | 0.18% |
| GLDM | -5.69% | $15.74B | 0.1% |
Yahoo
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Yahoo
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Yahoo
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
Yahoo
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
Yahoo
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Yahoo
A Relative Strength Rating upgrade for Incyte shows improving technical performance. Will it continue?
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRNT | 39.32% | $893.86M | +32.71% | 0.00% |
| CIM | 34.70% | $1.15B | +11.34% | 10.31% |
| JAZZ | 34.54% | $6.65B | +6.17% | 0.00% |
| FSP | 34.04% | $183.31M | +14.19% | 2.26% |
| GRMN | 33.07% | $41.09B | +32.42% | 1.47% |
| DT | 31.56% | $16.38B | +21.81% | 0.00% |
| PRAA | 31.36% | $609.95M | -21.85% | 0.00% |
| RYAM | 31.01% | $274.44M | -24.31% | 0.00% |
| CAKE | 30.92% | $3.23B | +75.36% | 1.67% |
| V | 30.62% | $686.89B | +31.69% | 0.64% |
| ADP | 30.39% | $123.83B | +28.76% | 1.97% |
| OMCL | 29.54% | $1.40B | +11.36% | 0.00% |
| FTNT | 29.43% | $78.23B | +68.30% | 0.00% |
| MA | 29.42% | $509.89B | +25.29% | 0.50% |
| PAYO | 29.30% | $2.51B | +26.69% | 0.00% |
| BRSP | 28.66% | $682.32M | -10.45% | 12.11% |
| PRI | 28.64% | $9.03B | +16.59% | 1.40% |
| D | 28.56% | $48.97B | +16.68% | 4.65% |
| BBU | 28.46% | $2.34B | +39.20% | 0.96% |
| BRBR | 28.34% | $7.30B | -2.71% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBTH | 0.03% | $1.62B | 0.07% |
| SIVR | -0.15% | $1.98B | 0.3% |
| UCON | 0.18% | $2.96B | 0.86% |
| CMF | 0.19% | $3.59B | 0.08% |
| DBO | -0.19% | $228.24M | 0.77% |
| MMIN | -0.21% | $336.10M | 0.3% |
| IBMS | 0.22% | $89.64M | 0.18% |
| MLN | -0.27% | $541.74M | 0.24% |
| TFI | 0.27% | $3.22B | 0.23% |
| DBE | -0.29% | $52.20M | 0.77% |
| COMT | 0.30% | $604.69M | 0.48% |
| DBC | 0.34% | $1.23B | 0.87% |
| SLV | 0.55% | $17.19B | 0.5% |
| BILZ | -0.58% | $821.74M | 0.14% |
| GSST | 0.61% | $921.46M | 0.16% |
| LMBS | -0.64% | $5.11B | 0.64% |
| CERY | 0.69% | $458.93M | 0.28% |
| BSCQ | 0.69% | $4.24B | 0.1% |
| UTWO | -0.69% | $379.52M | 0.15% |
| BSMR | -0.76% | $255.87M | 0.18% |
